Dr. Lanzkron's major clinical research involves the study of sickle cell disease. Her primary research interest is to understand the barriers to care for adults with sickle cell disease. In 1998 the FDA approved the use of hydroxyurea to treat patients with sickle cell disease. This approval was based on a large clinical trial centered at Johns Hopkins. The use of hydroxyurea was predicted to decrease hospitalizations and the costs of care for those with sickle cell disease. Dr. Lanzkron's research has shown that despite the approval of hydroxyurea, the costs of caring for patients with sickle cell disease has increases significantly over the last seven years. Research is ongoing to identify the factors that limit access to care for this population. The Sickle Cell Center for Adults at Johns Hopkins under Dr. Lanzkron's directions provides comprehensive care to adults.